The good news is that treatment options for lung cancer patients are rapidly improving. In the last two years, more treatments have been approved by the United States Food and Drug Administration (FDA) for the treatment of lung cancer than had been approved in the prior ten years. New and life saving treatments, along with clinical trials, are happening rapidly and LCFA is committed to keeping you up to date on the latest, most hopeful and helpful, information.
From Globe Newswire Biodesix® will release new data demonstrating the potential diagnostic utility of a blood-based test for patients with resistance to osimertinib, and on the precision of liquid biopsy in comparison to tissue biopsy. Two…
From UCLA Thoracic Oncology Translational Research Current and open clinical trials have been announced at UCLA Main Campus and various satellite centers. The trials include: Clinical Trial: Relapsed or Refractory Small Cell Lung Cancer …
From FDA.gov Combination Therapy for SCLC On March 18, 2019, the Food and Drug Administration approved atezolizumab (TECENTRIQ, Genentech Inc.) in combination with carboplatin and etoposide, for the first-line treatment of adult patients …
From COLORADO SPRINGS, Colo. (KKTV) January was National Radon Action Month Radon and Lung cancer: “Radon is a clear, odorless, colorless radioactive gas that seeps through the soil from the breakdown of uranium,” said Marla Luckey,…
from MIT News Bacteria promote lung tumor development, study suggests MIT cancer biologists have discovered a new mechanism that lung tumors exploit to promote their own survival: These tumors alter bacterial populations within the lung, pr…
from OncLive The scope of targeted therapies has extended more in non–small cell lung cancer (NSCLC), especially with the recent FDA approval of larotrectinib (Vitrakvi) for patients with NTRK gene fusions irrespective of the primary tumor…
From Medical Express Molecular profiling to catch lung cancer early The world's first genetic sequencing of precancerous lung lesions could pave the way for very early detection and new treatments, reports a new study led by University Coll…
From MedExpress Lung cancer remains a major cause of mortality across the globe, although we are gaining a deeper understanding of the genetic background behind this disease, including the mutations that promote it. Mutation in the gene EGFR…
How bias in the medical community hurts lung cancer patients. from The Washington Post Not long ago, I was working in a busy teaching hospital’s intensive-care unit, poring over EKGs, examining X-rays and reviewing medication orders. I re…
from EurekAlert University of Colorado Study Patients now living a median 6.8 years: According to the National Cancer Institute, patients diagnosed with non-small cell lung cancer (NSCLC) between the years 1995 and 2001 had 15 percent chan…